Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca Gay

Showing results (71-80 of 174) with videos related to

Pageof 18
Sort By:
Current Drug Targets|August 12, 2009
First-line treatment of multiple myeloma in elderly patients: the GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) multiple myeloma working party perspectivePellegrino Musto, Fiorella D'Auria, Giuseppe Pietrantuono, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension|January 22, 2025
Blood pressure variability as predictor of cancer therapy-related cardiovascular toxicity in patients with Multiple MyelomaElvira Fanelli, Giulia Picca, Lorenzo Airale, et al.
Frontiers in Cardiovascular Medicine|May 10, 2021
Effects of Carfilzomib Therapy on Left Ventricular Function in Multiple Myeloma PatientsGiulia Mingrone, Anna Astarita, Lorenzo Airale, et al.
Plos One|August 27, 2024
Developing and validating a discrete-event simulation model of multiple myeloma disease outcomes and treatment pathways using a national clinical registryAdam Irving, Dennis Petrie, Anthony Harris, et al.
Blood|December 4, 2015
Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myelomaNiels W C J van de Donk, Philippe Moreau, Torben Plesner, et al.
Cancers|April 30, 2021
Multiple Myeloma Patients Undergoing Carfilzomib: Development and Validation of a Risk Score for Cardiovascular Adverse Events PredictionAnna Astarita, Giulia Mingrone, Lorenzo Airale, et al.
Haematologica|July 13, 2014
Chromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapiesSimona Caltagirone, Marina Ruggeri, Simona Aschero, et al.
Clinical Lymphoma & Myeloma|May 2, 2009
Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event resultsAntonio Palumbo, Patrizia Falco, Antonietta Falcone, et al.
Haematologica|January 8, 2010
Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trialAntonio Palumbo, Alessandra Larocca, Mariella Genuardi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 4, 2020
Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation SequencingMattia D'Agostino, Gian Maria Zaccaria, Bachisio Ziccheddu, et al.
Pageof 18

Showing results (71-80 of 174) with videos related to

Sort By:
Pageof 18
Current Drug Targets|August 12, 2009
First-line treatment of multiple myeloma in elderly patients: the GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) multiple myeloma working party perspectivePellegrino Musto, Fiorella D'Auria, Giuseppe Pietrantuono, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension|January 22, 2025
Blood pressure variability as predictor of cancer therapy-related cardiovascular toxicity in patients with Multiple MyelomaElvira Fanelli, Giulia Picca, Lorenzo Airale, et al.
Frontiers in Cardiovascular Medicine|May 10, 2021
Effects of Carfilzomib Therapy on Left Ventricular Function in Multiple Myeloma PatientsGiulia Mingrone, Anna Astarita, Lorenzo Airale, et al.
Plos One|August 27, 2024
Developing and validating a discrete-event simulation model of multiple myeloma disease outcomes and treatment pathways using a national clinical registryAdam Irving, Dennis Petrie, Anthony Harris, et al.
Blood|December 4, 2015
Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myelomaNiels W C J van de Donk, Philippe Moreau, Torben Plesner, et al.
Cancers|April 30, 2021
Multiple Myeloma Patients Undergoing Carfilzomib: Development and Validation of a Risk Score for Cardiovascular Adverse Events PredictionAnna Astarita, Giulia Mingrone, Lorenzo Airale, et al.
Haematologica|July 13, 2014
Chromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapiesSimona Caltagirone, Marina Ruggeri, Simona Aschero, et al.
Clinical Lymphoma & Myeloma|May 2, 2009
Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event resultsAntonio Palumbo, Patrizia Falco, Antonietta Falcone, et al.
Haematologica|January 8, 2010
Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trialAntonio Palumbo, Alessandra Larocca, Mariella Genuardi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 4, 2020
Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation SequencingMattia D'Agostino, Gian Maria Zaccaria, Bachisio Ziccheddu, et al.
Pageof 18